Physician profile
Emily Freimuth
NPI 1639550981
$2,631.52
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $809 · 2023: $703 · 2024: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,347 · Education: $5.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.45 |
| Education | $5.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $643.56 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $394.68 | 2021-2024 | |
| Alkermes, INC. | $381.89 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $250.81 | 2021-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $207.23 | 2022-2024 | Ingrezza |
| Lundbeck LLC | $162.31 | 2022-2024 | Abilify Maintena |
| Vanda Pharmaceuticals INC. | $130.58 | 2021-2024 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.31 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $81.71 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $73.32 | 2022-2023 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $57.91 | 2023-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $56.87 | 2022 | |
| Indivior INC. | $30.27 | 2022-2023 | Perseris |
| Corium, LLC | $15.26 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.82 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $13.07 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Freimuth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.